Mentari Therapeutics, Inc. (MTRI)
12.22
-3.78
(-23.62%)
USD |
NASDAQ |
Nov 10, 16:00
12.80
+0.58
(+4.75%)
After-Hours: 16:29
Mentari Therapeutics Enterprise Value : 86.76M for Nov. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 09, 2026 | 86.76M |
| November 06, 2026 | 84.35M |
| November 05, 2026 | 71.44M |
| November 04, 2026 | 95.00M |
| November 03, 2026 | 91.16M |
| November 02, 2026 | 88.41M |
| October 30, 2026 | 86.76M |
| October 29, 2026 | 88.14M |
| October 28, 2026 | 86.72M |
| October 27, 2026 | 86.22M |
| October 26, 2026 | 86.22M |
| October 23, 2026 | 77.97M |
| October 22, 2026 | 71.93M |
| October 21, 2026 | 73.58M |
| October 20, 2026 | 72.48M |
| October 19, 2026 | 73.88M |
| October 16, 2026 | 71.38M |
| October 15, 2026 | 71.93M |
| October 14, 2026 | 70.83M |
| October 13, 2026 | 71.93M |
| October 12, 2026 | 73.58M |
| October 09, 2026 | 73.58M |
| October 08, 2026 | 71.93M |
| October 07, 2026 | 71.93M |
| October 06, 2026 | 71.93M |
| Date | Value |
|---|---|
| October 05, 2026 | 71.93M |
| October 02, 2026 | 71.93M |
| October 01, 2026 | 73.03M |
| September 30, 2026 | 73.58M |
| September 29, 2026 | 71.18M |
| September 28, 2026 | 70.38M |
| September 25, 2026 | 71.45M |
| September 24, 2026 | 72.52M |
| September 23, 2026 | 71.45M |
| September 22, 2026 | 71.98M |
| September 21, 2026 | 71.45M |
| September 18, 2026 | 70.38M |
| September 17, 2026 | 71.98M |
| September 16, 2026 | 66.11M |
| September 15, 2026 | 66.11M |
| September 14, 2026 | 67.18M |
| September 11, 2026 | 66.64M |
| September 10, 2026 | 67.71M |
| September 09, 2026 | 67.71M |
| September 08, 2026 | 68.78M |
| September 04, 2026 | 71.45M |
| September 03, 2026 | 68.78M |
| September 02, 2026 | 69.85M |
| September 01, 2026 | 68.25M |
| August 31, 2026 | 69.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NervGen Pharma Corp. | 87.27M |
| Milestone Pharmaceuticals, Inc. | 63.10M |
| Appili Therapeutics, Inc. | 9.56M |
| Clearmind Medicine, Inc. | -12.66M |
| Lexaria Bioscience Corp. | 3.578M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.995M |
| Total Expenses (Quarterly) | 1.995M |
| EPS Diluted (Quarterly) | -0.4261 |
| Earnings Yield | -25.41% |
| Normalized Earnings Yield | -23.26 |